Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HAE 
Haemonetics Corporation (HAE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: HAE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -24.16% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.17B USD | Price to earnings Ratio 24.81 | 1Y Target Price 96.4 |
Price to earnings Ratio 24.81 | 1Y Target Price 96.4 | ||
Volume (30-day avg) 822321 | Beta 0.43 | 52 Weeks Range 58.80 - 97.97 | Updated Date 04/1/2025 |
52 Weeks Range 58.80 - 97.97 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.47% | Operating Margin (TTM) 18.97% |
Management Effectiveness
Return on Assets (TTM) 6.33% | Return on Equity (TTM) 14.06% |
Valuation
Trailing PE 24.81 | Forward PE 12.64 | Enterprise Value 4136786176 | Price to Sales(TTM) 2.32 |
Enterprise Value 4136786176 | Price to Sales(TTM) 2.32 | ||
Enterprise Value to Revenue 2.97 | Enterprise Value to EBITDA 13.8 | Shares Outstanding 50237500 | Shares Floating 49750665 |
Shares Outstanding 50237500 | Shares Floating 49750665 | ||
Percent Insiders 0.89 | Percent Institutions 116.36 |
Analyst Ratings
Rating 4.1 | Target Price 110.8 | Buy 5 | Strong Buy 3 |
Buy 5 | Strong Buy 3 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Haemonetics Corporation
Company Overview
History and Background
Haemonetics Corporation was founded in 1971. Initially focused on blood processing technology, it has evolved into a global provider of blood and plasma component collection, processing, and storage solutions.
Core Business Areas
- Plasma: Solutions for plasma collection, including devices and disposables used in plasma centers.
- Blood Center: Products for blood collection, processing, and storage in blood banks.
- Hospital: Solutions for blood management in hospitals, including cell salvage and transfusion management systems.
Leadership and Structure
Ronald Gelok is currently the CEO. The company has a typical corporate structure with various departments reporting to the CEO and executive leadership team.
Top Products and Market Share
Key Offerings
- PCS Plasma Collection System: Automated system for collecting plasma. Competitors include Terumo BCT and Grifols. Market share for automated plasma collection systems is competitive, but Haemonetics is a major player. Estimated revenue can be found in their quarterly reports.
- Cell Saver Elite+ Autotransfusion System: System for recovering and re-infusing a patient's own blood during surgery. Competitors include LivaNova. Haemonetics holds a significant market share in cell salvage technology. Estimated revenue can be found in their quarterly reports.
- NexSys PCS System: Advanced plasma collection technology. Competitors include Terumo BCT. Market share is growing due to its efficiency. Estimated revenue can be found in their quarterly reports.
Market Dynamics
Industry Overview
The blood and plasma component industry is growing, driven by increasing demand for blood products and plasma-derived therapies.
Positioning
Haemonetics is a leading player with strong positions in plasma collection and hospital blood management. It competes on technology, service, and cost.
Total Addressable Market (TAM)
The global blood and plasma products market is estimated at $40 billion. Haemonetics is well-positioned within its segments to capture a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Strong market position in plasma collection
- Innovative product portfolio
- Established customer base
- Global presence
Weaknesses
- Dependence on plasma collection market
- Exposure to regulatory changes
- Competition from larger players
- Fluctuations in hospital spending
Opportunities
- Expanding into emerging markets
- Developing new blood management technologies
- Acquiring complementary businesses
- Increasing demand for plasma-derived therapies
Threats
- Pricing pressure from competitors
- Disruptive technologies
- Changes in reimbursement policies
- Economic downturns
Competitors and Market Share
Key Competitors
- TER
- BDX
- GRFS
Competitive Landscape
Haemonetics competes effectively in its chosen segments, leveraging its technology and established customer relationships. However, it faces strong competition from larger, diversified healthcare companies.
Major Acquisitions
Cardiva Medical, Inc.
- Year: 2021
- Acquisition Price (USD millions): 510
- Strategic Rationale: Expanded Haemonetics' portfolio into vascular closure systems for electrophysiology and interventional cardiology procedures.
Growth Trajectory and Initiatives
Historical Growth: Haemonetics has demonstrated moderate growth in recent years, driven by expansion in its core markets and strategic acquisitions.
Future Projections: Analyst estimates project continued growth in revenue and earnings, fueled by increasing demand for blood and plasma products. Estimates are not included here but would vary and be based on public data.
Recent Initiatives: Recent initiatives include investments in new product development, geographic expansion, and strategic acquisitions.
Summary
Haemonetics is a solid company in the blood and plasma component industry, with a leading position in plasma collection and cell salvage. Its innovative products and global presence are key strengths. However, it needs to manage competition and regulatory risks effectively. Growth opportunities lie in emerging markets and new blood management technologies. Overall Haemonetics seems to be positioned for continued growth in the market.
Similar Companies
- TER
- BDX
- GRFS
- LH
Sources and Disclaimers
Data Sources:
- Haemonetics Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haemonetics Corporation
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 1991-05-09 | CEO, President & Director Mr. Christopher A. Simon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3657 | Website https://www.haemonetics.com |
Full time employees 3657 | Website https://www.haemonetics.com | ||
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.